Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

5.10
-0.1800-3.41%
Post-market: 5.100.00000.00%16:10 EDT
Volume:32.07K
Turnover:164.04K
Market Cap:51.23M
PE:-2.11
High:5.27
Open:5.24
Low:5.05
Close:5.28
52wk High:29.98
52wk Low:4.32
Shares:10.04M
Float Shares:8.83M
Volume Ratio:0.52
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4137
EPS(LYR):0.6400
ROE:-66.57%
ROA:-39.85%
PB:1.48
PE(LYR):7.97

Loading ...

Seres Therapeutics Explores Partnerships to Advance Ser-155 Development in Immune Checkpoint Inhibitor-related Enterocolitis

Reuters
·
Jul 08

Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell

MT Newswires Live
·
Jul 08

Seres Therapeutics announces top-line results from SER-155 trial

TIPRANKS
·
Jul 08

Seres Therapeutics Announces Press Release Availability

Reuters
·
Jul 08

Seres Reports Early Data Showing Ser-155 Eases Ici-related Enterocolitis Without Systemic Immunosuppressives in MSK Trial

Reuters
·
Jul 08

Seres Therapeutics - Ser-155 Well Tolerated with no Drug-related Serious Adverse Events Through Day 43

THOMSON REUTERS
·
Jul 08

Seres Therapeutics Announces Early Clinical Data Showing Potential for Ser-155 in Immune Checkpoint Inhibitor-related Enterocolitis (irec), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

THOMSON REUTERS
·
Jul 08

Seres Therapeutics - 80% of Ser-155 Recipients Achieve Immunosuppressive-free Response at Day 15 in Ist

THOMSON REUTERS
·
Jul 08

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

GlobeNewswire
·
Jul 08

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

GlobeNewswire
·
Jun 25

Seres Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 23

Seres Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $12

THOMSON REUTERS
·
Jun 23

Seres Therapeutics announces two transactions

TIPRANKS
·
Jun 05

Seres Therapeutics Reshapes Finances with Lease Restructuring

TIPRANKS
·
Jun 05

BRIEF-Seres Therapeutics Announces Two Transactions To Strengthen Balance Sheet, Reduce On-Going Lease Costs And Extend Projected Operating Cash Runway Well Into The First Quarter Of 2027

Reuters
·
Jun 05

Seres Therapeutics amends Vowst deal, secures USD 25 million milestone buyout from Nestlé Health Science

Reuters
·
Jun 05

Seres Therapeutics - Restructures Lease to Reduce Annual Facility Cash Costs and Long-Term Lease Liability

THOMSON REUTERS
·
Jun 05

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce on-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

THOMSON REUTERS
·
Jun 05

Seres Therapeutics - NestlÉ Health Science to Pay Seres $25 Mln in 2026 for Vowst Milestone Buy-Out

THOMSON REUTERS
·
Jun 05

Seres Therapeutics director Hans-Juergen Woerle resigns from board

Reuters
·
Jun 02